Myositis News, Research, and MSU Updates

Information from Orphazyme A/S about the Clinical Development of Arimoclomol in sIBM during the COVID-19 Pandemic

Patients with sporadic inclusion body myositis (sIBM), together with their care partners, have been asking questions about the clinical trial of Arimoclomol during the COVID-19 pandemic. Inclusion body myositis has no approved therapies and there is substantial interest in this clinical trial. In the myositis community, we are following it closely.

Participants in the trial have been wondering how they will be protected during social isolation/distancing while also meeting their required clinical trial healthcare visits and testing, and about how COVID-19 impacts the trial overall.

We have been in regular contact with the amazing team at Orphazyme and we are happy to provide you with a statement that addresses some of these important questions.

A message from Orphazyme to the global community of patients, family members and healthcare providers impacted by the coronavirus pandemic (COVID-19) (PDF)

We thank Orphazyme, a sponsor of MSU, for their commitment to keeping us informed and safe.




Myositis Support and Understanding Association (MSU) is a patient-centered, all-volunteer 501(c)(3) nonprofit organization Empowering the Myositis Community. Founded by Myositis patients, for Myositis patients, MSU provides education, support, advocacy, access to research and clinical trial matching, and need-based financial assistance.

View more information: Myositis Support


Leave a reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.

© 2022 Myositis Support and Understanding Association (MSU). All rights reserved. | View our Privacy Policy, Terms, and Non-Discrimination policy. MSU is a charitable organization with 501(c)(3) tax-exempt status. Federal ID #47-4570748.

View COVID-19 resources and updates, and stay tuned to your state, local, and federal health agencies, along with the CDC.

Log in with your credentials


Forgot your details?

Create Account

Send this to a friend